A METABRIC analysis of breast cancer patients that received only endocrine treatment linked TP53 mutations to worse survival [6], while a meta-analysis of 3,476 cases of patients receiving neoadjuvant treatment concluded that TP53 mutation status is a predictor of response to neoadjuvant chemotherapy [14]. This evidence concerns the gene TP53 and breast cancer.